StockTitan

@stocktitan.net

10 hours ago

SCIENTURE Reports Year End 2025 Financial Results and Provides Business Update SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to

#SCNX SCIENTURE Reports Year End 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/SCNX/scienture-repo...

StockTitan

@stocktitan.net

2 weeks ago

SCIENTURE Broadens Commercial Access for REZENOPY™, Highest-Dose FDA-Approved Naloxone Nasal Spray, Through GPO Agreements Reaching Over 5,000 U.S. Institutions Scienture (NASDAQ: SCNX) announced GPO agreements giving REZENOPY™ (naloxone HCl) Nasal Spray 10 mg access to more than 5,000 healthcare institutions, representing potential penetration of roughly 60% of the U.S. institutional market. REZENOPY™ is the highest-dose FDA-approved naloxone nasal spray.IQVIA (MAT Jan 2026) shows the U.S. naloxone market at $141M annual sales with 9.4M prescription units, highlighting a defined commercial opportunity for broader institutional adoption through hospitals, EMS, and rehabilitation centers.

#SCNX SCIENTURE Broadens Commercial Access for REZENOPY™, Highest-Dose FDA-Approved Naloxone Nasal Spray, Through GPO Agreements Reaching Over 5,000 U.S. Institutions

www.stocktitan.net/news/SCNX/scienture-broa...

StockTitan

@stocktitan.net

3 months ago

SCIENTURE Provides Update on the Commercial Launch of REZENOPY®, the Highest Strength Naloxone HCl Life-Saving Opioid Overdose Emergency Treatment Approved by the FDA SCIENTURE (NASDAQ: SCNX) provided an update on the commercial launch of REZENOPY® (naloxone HCl) Nasal Spray 10 mg, the highest-strength FDA-approved naloxone product. Scienture acquired exclusive U.S. commercialization rights in March 2025 and notes FDA approval occurred on April 19, 2024. IQVIA data (MAT September 2025) shows the U.S. naloxone market at approximately $154 million in annual sales and 9.3 million units annually. Manufacturing is reported to be on track with product readiness expected in Q1 2026, wholesale loading in Q1 2026, and commercial availability beginning in early Q2 2026.

#SCNX SCIENTURE Provides Update on the Commercial Launch of REZENOPY®, the Highest Strength Naloxone HCl Life-Saving Opioid Overdose Emergency Treatment Approved by the FDA

www.stocktitan.net/news/SCNX/scienture-prov...

StockTitan

@stocktitan.net

3 months ago

SCIENTURE and BlinkRx Announce Strategic Collaboration to Expand Patient Access to Arbli™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium SCIENTURE (NASDAQ: SCNX) announced a strategic collaboration with BlinkRx to expand national access to Arbli™, the first FDA-approved ready-to-use oral suspension of losartan potassium. Arbli™ is expected to be available on the BlinkRx platform in Q1 2026. The U.S. losartan market totals about $245M in annual sales with roughly 71 million prescriptions (IQVIA MAT Sept 2025). BlinkRx reports it helps 52% more patients start therapy and keeps them on medication 40% longer, which Scienture says may increase starts, duration, and affordability for patients needing suspension formulations.

#SCNX SCIENTURE and BlinkRx Announce Strategic Collaboration to Expand Patient Access to Arbli™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium

www.stocktitan.net/news/SCNX/scienture-and-...

StockTitan

@stocktitan.net

4 months ago

SCIENTURE Reports Q3 2025 Financial Results and Provides Business Update SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a

#SCNX SCIENTURE Reports Q3 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/SCNX/scienture-repo...

@wallstreetpulse.bsky.social

4 months ago

$SCNX, Deep Dive Analysis of Scienture Holdings, Inc, ticker SCNX YouTube video by Hisseseven

youtu.be/jyvIv8FiNpE?... #$SCNX #SCNX

StockTitan

@stocktitan.net

4 months ago

SCIENTURE Announces Addition of Arbli™ (Losartan Potassium) to Formularies of Major National Health Plans SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and

#SCNX SCIENTURE Announces Addition of Arbli™ (Losartan Potassium) to Formularies of Major National Health Plans

www.stocktitan.net/news/SCNX/scienture-anno...

Market Wire News

@marketwirenews.com

5 months ago

Breaking News: ( NASDAQ: #SCNX ) US Companies Moving the Markets, Morning edition <br>Fri, Oct 24, 2025 as of 10.00 am ET

Stock Master

@stockmaster70.bsky.social

5 months ago

📢 Stocks Trending NOW: #INTC #PG #DECK #SCNX #WGRX #GNTA #QLGN #VIVK #ITGR #GD

Market Wire News

@marketwirenews.com

5 months ago

JUST IN: ( NASDAQ: #SCNX ) Pharma Stock SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) Makes Nasdaq Top Gainer on News of Commercial Sales and Fulfillment of First Orders for Arbli

Small Cap Strategist

@smcapstrategist.bsky.social

5 months ago

Small-cap stocks oversold with improving relative strength, Thu Oct 23rd - #LXEH #SCNX #STRZ #LFVN - More: crystalequityresearch.com/leading-indi... - #smallcap

StockTitan

@stocktitan.net

5 months ago

SCIENTURE Announces Start of Commercial Sales and Fulfillment of First Orders for Arbli™ (Losartan Potassium) Company launches multi-channel promotional campaign to drive market adoption U.S. losartan market totals $256M annually with 71M prescriptions, creating a significant opportunity for Arbli™ as the first FDA-approved ready-to-use oral suspension COMMACK, NY, Oct. 23, 2025 (GLOBE NEWSWIRE) --

#SCNX SCIENTURE Announces Start of Commercial Sales and Fulfillment of First Orders for Arbli™ (Losartan Potassium)

www.stocktitan.net/news/SCNX/scienture-anno...

StockTitan

@stocktitan.net

5 months ago

SCIENTURE’S Arbli™ Becomes First FDA-Approved Ready-to-Use Liquid Losartan Available Through Major U.S. Wholesalers Scienture Holdings (NASDAQ: SCNX) announced that Arbli™ (losartan potassium) Oral Suspension, 10mg/mL is commercially available through full-line wholesalers nationwide as of Oct 16, 2025.Arbli is described as the first FDA-approved ready-to-use liquid losartan, targeting patients unable to swallow tablets (including elderly and children six and older). The U.S. losartan market is noted at $256M annually with 71M prescriptions, positioning Arbli as a new entrant into the broader hypertension market and a replacement for inconsistent compounded liquids.

#SCNX SCIENTURE’S Arbli™ Becomes First FDA-Approved Ready-to-Use Liquid Losartan Available Through Major U.S. Wholesalers

www.stocktitan.net/news/SCNX/scienture-s-ar...

StockTitan

@stocktitan.net

5 months ago

SCIENTURE Secures Multiple Commercial GPO Agreements, Expanding U.S. Market Access for Arbli™ (losartan potassium) to more than 2500 Healthcare Institutions Represents potential penetration into ~ 20% of the U.S. institutional market, while broadening access across long-term care and outpatient facilities U.S. losartan market totals $256M annually with 71M prescriptions, creating a significant opportunity for Arbli ™ as the first FDA-approved

#SCNX SCIENTURE Secures Multiple Commercial GPO Agreements, Expanding U.S. Market Access for Arbli™ (losartan potassium) to more than 2500 Healthcare Institutions

www.stocktitan.net/news/SCNX/scienture-secu...

StockTitan

@stocktitan.net

6 months ago

SCIENTURE Secures PBM-Led GPO Rebate Agreement to Drive Expanded Commercial Coverage and Formulary Access for Arbli™(losartan potassium) in the $256M U.S. Losartan Market SCIENTURE (NASDAQ:SCNX) has secured a major PBM-led GPO rebate agreement for Arbli™ (losartan potassium), their FDA-approved liquid formulation of losartan. This agreement advances formulary access with health plans covering over 100 million lives.Arbli™ is the first and only ready-to-use liquid losartan in the U.S., targeting the $256 million losartan market with 71 million prescriptions annually. The product is approved for treating hypertension in patients over six years old, reducing stroke risk in hypertensive patients with left ventricular hypertrophy, and treating diabetic nephropathy in certain type 2 diabetes patients.The proprietary formulation offers advantages including reduced dosing volume, room-temperature stability, and elimination of compounding needs, protected by two USPTO patents listed in the FDA Orangebook.

#SCNX SCIENTURE Secures PBM-Led GPO Rebate Agreement to Drive Expanded Commercial Coverage and Formulary Access for Arbli™(losartan potassium) in the $256M U.S. Losartan Market

www.stocktitan.net/news/SCNX/scienture-secu...

Market Wire News

@marketwirenews.com

7 months ago

Breaking News: ( NASDAQ: #SCNX ) US Companies Moving the Markets, Evening edition <br>Thu, Aug 14, 2025 as of 4:00 pm ET

StockTitan

@stocktitan.net

7 months ago

Scienture Secures $3.9M Investment from Institutional Buyers at $1.20 Per Share Pharma specialty products developer Scienture Holdings raises $3.9M through institutional stock offering at $1.20 per share, with closing expected August 15. See details.

#SCNX Scienture Holdings, Inc. Announces Pricing of $3.9 Million Registered Direct Offering of Common Stock

www.stocktitan.net/news/SCNX/scienture-hold...

StockTitan

@stocktitan.net

8 months ago

Scienture Holdings, Inc. Obtains $1.2 Million in Bridge Funding Scienture Holdings (NASDAQ: SCNX) has secured $1.2 million in bridge funding through common stock issuance to institutional/accredited investors, as part of a larger approved raise of up to $3 million. The funding excludes any additional dilutive securities like warrants or options.The capital will support upcoming commercial product launches and pipeline program development. The company's leadership, including Executive Chairman Shankar Hariharan and Co-CEO Narasimhan Mani, emphasized that this funding reflects investor confidence in their strategy to develop and market specialty pharmaceutical products.

#SCNX Scienture Holdings, Inc. Obtains $1.2 Million in Bridge Funding

www.stocktitan.net/news/SCNX/scienture-hold...

StockTitan

@stocktitan.net

9 months ago

Scienture Terminates $310M Credit Line to Focus on Revolutionary Liquid Hypertension Drug Launch Strategic move positions Scienture for Q3 launch of Arbli, first-ever FDA-approved liquid losartan. See how this impacts growth strategy and market potential.

#SCNX Scienture Holdings Announces Cancelation of ELOC

www.stocktitan.net/news/SCNX/scienture-hold...

StockTitan

@stocktitan.net

10 months ago

SCIENTURE announces FDA Orange Book Patent Listing for ArbliTM, (losartanpotassium) Oral Suspension, 10mg/mL. Scienture Holdings (NASDAQ: SCNX) announces FDA Orange Book listing of two patents for Arbli™, their losartan potassium oral suspension. The patents (11890273 and 12156869), expiring in October 2041, cover stable liquid formulations and treatment methods for Arbli™, the first FDA-approved ready-to-use oral liquid losartan in the U.S.Arbli™ (10mg/mL) is approved for treating hypertension in patients over 6 years old, reducing stroke risk in hypertensive patients with left ventricular hypertrophy, and treating diabetic nephropathy in type 2 diabetes patients. The product addresses the limitations of current tablet-only options, eliminating compounding risks and offering convenient dosing.According to IQVIA data (March 2025), the U.S. losartan market shows annual sales of $276 million with 69 million prescriptions.

#SCNX SCIENTURE announces FDA Orange Book Patent Listing for ArbliTM, (losartanpotassium) Oral Suspension, 10mg/mL.

www.stocktitan.net/news/SCNX/scienture-anno...

StockTitan

@stocktitan.net

11 months ago

Revolutionary Liquid Losartan Targets $292M Market: First FDA-Approved Formula Challenges Traditional Tablets First ready-to-use liquid losartan secures manufacturing pipeline for July 2025 launch. Targeting 68M prescription market. Get exclusive launch details.

#SCNX SCIENTURE announces manufacturing and supply chain readiness for ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL for a target product launch in July 2025.

www.stocktitan.net/news/SCNX/scienture-anno...

StockTitan

@stocktitan.net

11 months ago

Scienture Holdings, Inc. Issues Annual Letter to Shareholders Scienture Holdings (NASDAQ: SCNX) has transformed from a health services IT company to a specialty pharmaceutical company through strategic moves in 2024-2025. The company completed a $22.5M sale of TRXaDE Inc. assets and merged with Scienture Inc. in a $103M all-stock transaction.The company now has two FDA-approved commercial products scheduled for launch in H2 2025: ArbliTM (in-house developed) and REZENOPY® (acquired in March 2025). The company's pipeline includes multiple products under development:SCN-104: Injectable pen for migraine treatmentSCN-106: CVS therapeutic biosimilarSCN-107: Non-opioid post-surgical pain managementREZENOPY®, a 10mg naloxone HCl nasal spray, targets a market with annual sales of $189M. The combined market opportunity for their two commercial products is $481M, based on IQVIA data (December 2024).

#SCNX Scienture Holdings, Inc. Issues Annual Letter to Shareholders

www.stocktitan.net/news/SCNX/scienture-hold...

StockTitan

@stocktitan.net

1 year ago

Scienture Gears Up for Major Product Launch: New CCO and Syneos Health Partnership Signal Growth Scienture appoints pharma veteran as CCO and partners with Syneos Health to accelerate commercialization of two FDA-approved products. Full launch strategy inside.

#SCNX SCIENTURE Announces Commercial Operations Leadership and Strategic Agreement with Syneos Health, a leading Contract Sales Organization

www.stocktitan.net/news/SCNX/scienture-anno...

StockTitan

@stocktitan.net

1 year ago

FDA Approves Revolutionary Liquid Losartan: Scienture's Game-Changing Hypertension Treatment Scienture's Arbli™, the first FDA-approved liquid losartan, targets Q3 2025 launch. Strategic ELOC draw supports commercialization while protecting shareholder value.

#SCNX Scienture Holdings Announces Draw on ELOC, Temporarily Suspends Further Draws Until Reaching $10/Share or 30 Trading Days

www.stocktitan.net/news/SCNX/scienture-hold...

Small Cap Strategist

@smcapstrategist.bsky.social

1 year ago

Most searched small-cap stocks, Tue Mar 18th - #PTON #APLD #TGB #CLSK #TIGR #WULF #IQ #BBAI #BTE #SCNX #ADTX #WOLF #UUUU #UEC #SMR #RGTI #QUBT #QBTS #LUNR #JSPR - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Small Cap Strategist

@smcapstrategist.bsky.social

1 year ago

Most searched small-cap stocks, Thu Mar 6th - #FUBO #RXRX #AG #AQN #APLD #NGD #VRN #WULF #RIOT #IQ #QBTS #SCNX #ACON #CORZ #UUUU #WCT #RGTI #LUNR #GV #LAES - More: crystalequityresearch.com/SmCpStr/ - #smallcap

StockTitan

@stocktitan.net

1 year ago

Can This New High-Strength Naloxone Treatment Transform the $189M Opioid Crisis Market? Scienture secures exclusive US rights for REZENOPY, the highest-strength naloxone nasal spray, targeting $189M market through Kindeva partnership.

#SCNX SCIENTURE to commercially launch REZENOPY®, a life-saving opioid overdose emergency treatment through a collaboration with KINDEVA DRUG DELIVERY L.P.

www.stocktitan.net/news/SCNX/scienture-to-c...

StockTitan

@stocktitan.net

1 year ago

Scienture President to Keynote at Major SSX Pharma Conference, Spotlight Innovation Strategy Dr. Narasimhan Mani to present on tech-driven pharmaceutical innovations and market strategies at the 8th Annual SSX Conference in India, January 2025.

#SCNX Scienture Holdings, Inc. Announces Dr. Narasimhan Mani’s Participation in the 8th Annual Conference of The Society for the Study of Xenobiotics

www.stocktitan.net/news/SCNX/scienture-hold...

StockTitan

@stocktitan.net

1 year ago

Scienture Holdings to Present at Microcap Conference 2025: Strategic Growth Plans in Focus Scienture Holdings' management team will showcase their corporate strategy and meet with investors at The Microcap Conference 2025, discussing growth plans and opportunities.

#SCNX Scienture Holdings, Inc. Announces Participation in The Microcap Conference 2025

www.stocktitan.net/news/SCNX/scienture-hold...